Allergy Therapeutics plc (AGY.L)

3,1500 +0,0250 (+0,80%) Alla chiusura: 03:47PM BST

Allergy Therapeutics plc

Dominion Way
Worthing BN14 8SA
United Kingdom
44 1903 844 700
https://www.allergytherapeutics.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 612

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Manuel Llobet	CEO & Executive Director	411,98k	N/D	1965
Mr. Shaun Antony Furlong	CFO & Executive Director	N/D	N/D	1976
Ms. Beverly Lees	Group Operations Director	N/D	N/D	N/D
Dr. Murray Skinner	Chief Scientific Officer	N/D	N/D	N/D
Mr. Santiago Puig	Business Development Director	N/D	N/D	N/D
Ms. Sue Baker	Head of Human Resources	N/D	N/D	N/D
Simon Piggott	Head of Clinical Science	N/D	N/D	N/D
Alan Bullimore	Head of Communication & Market Development	N/D	N/D	N/D
Mr. Russell Picket	Group Financial Controller	N/D	N/D	N/D
Karley Charlotte Mouatt Cheesman	Company Secretary	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in GBp.

Descrizione

Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut. The company develops allergy vaccines for pollen, house dust mites, and animal fur, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Allergy Therapeutics plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.